Key Points
- CEO Bobak Azamian sold 10,972 shares on March 17 at an average price of $69.42 for total proceeds of $761,676.24, leaving him with 57,052 shares (a 16.13% reduction in his position).
- Significant insider selling occurred broadly between March 16–19 (including a director sale of 12,500 shares), disclosures that can pressure the stock and were filed with the SEC.
- Tarsus is a clinical‑stage ophthalmology company with a $2.84 billion market cap, reported a slight earnings miss but revenue above estimates last quarter, and carries a consensus analyst rating of "Moderate Buy" with a consensus target near $91.83 as some firms raised price targets.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $69.42, for a total value of $26,032.50. Following the completion of the transaction, the insider owned 24,077 shares in the company, valued at $1,671,425.34. The trade was a 1.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Elizabeth Yeu Lin also recently made the following trade(s):
- On Thursday, March 19th, Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $67.00, for a total value of $26,130.00.
- On Wednesday, March 18th, Elizabeth Yeu Lin sold 379 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $68.71, for a total value of $26,041.09.
Tarsus Pharmaceuticals Trading Down 0.6%
Shares of NASDAQ:TARS traded down $0.38 during trading on Friday, reaching $66.37. 45,653 shares of the stock were exchanged, compared to its average volume of 585,032. The firm's 50-day moving average price is $69.36 and its 200 day moving average price is $70.18. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -41.02 and a beta of 0.55. Tarsus Pharmaceuticals, Inc. has a 12-month low of $38.51 and a 12-month high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The business had revenue of $151.67 million during the quarter, compared to analysts' expectations of $144.56 million. On average, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.
Tarsus Pharmaceuticals News Roundup
Here are the key news stories impacting Tarsus Pharmaceuticals this week:
- Positive Sentiment: Lifesci Capital upgraded TARS to "Strong‑Buy" and published tighter quarterly and FY‑2026 EPS forecasts (smaller expected losses vs. consensus), which supports a more constructive growth/recovery thesis for the stock. Read More.
- Neutral Sentiment: Street consensus remains mixed-to-favorable (average "Moderate Buy"); Lifesci's upgrade improves outlook but does not represent unanimous conviction across all analysts. Read More.
- Neutral Sentiment: Company fundamentals: most recent quarter showed a slight EPS miss (reported ($0.20) vs. ($0.19) estimate) but revenue beat, leaving fundamentals mixed and dependent on future trial/launch catalysts. Read More.
- Neutral Sentiment: High institutional ownership (~90%) is a double‑edged factor — it stabilizes float but means large holders can move the stock if they adjust positions. Read More.
- Negative Sentiment: Significant insider selling disclosed in multiple Form 4s between Mar 16–19: CEO Bobak Azamian sold ~10.9k–12.0k shares across several days (prices ~ $67–$69), director William J. Link sold 12,500 shares (~$68.79), and several other senior officers also reduced stakes — these large, clustered sales can create immediate downward pressure and raise questions about near‑term liquidity needs or portfolio rebalancing. Read More.
Analysts Set New Price Targets
Several research analysts have commented on TARS shares. Mizuho assumed coverage on Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an "outperform" rating and a $100.00 price objective on the stock. The Goldman Sachs Group reiterated a "neutral" rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Monday. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, February 28th. Finally, Zacks Research lowered shares of Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $91.83.
Read Our Latest Stock Analysis on TARS
Institutional Trading of Tarsus Pharmaceuticals
A number of hedge funds have recently made changes to their positions in TARS. TimesSquare Capital Management LLC acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter worth $15,898,000. Jennison Associates LLC raised its stake in shares of Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company's stock valued at $154,790,000 after purchasing an additional 136,582 shares in the last quarter. TFG Asset Management GP Ltd lifted its position in shares of Tarsus Pharmaceuticals by 40.1% during the second quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company's stock worth $10,128,000 after purchasing an additional 71,530 shares during the last quarter. Capricorn Fund Managers Ltd acquired a new position in Tarsus Pharmaceuticals in the third quarter worth about $14,264,000. Finally, Jump Financial LLC grew its stake in Tarsus Pharmaceuticals by 385.9% in the second quarter. Jump Financial LLC now owns 237,117 shares of the company's stock worth $9,606,000 after purchasing an additional 188,317 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.
Tarsus Pharmaceuticals Company Profile
(
Get Free Report)
Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.
In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
